For Q1 2024, GDP growth in the United States decelerated to 1.6% from 3.4% in the last quarter. There is no doubt that factors like high interest rates and geopolitical tensions have impacted growth. At the same time, inflation has been relatively stubborn, and potential rate cuts will likely be delayed. The markets are, therefore, likely to witness some nervousness. From an investment perspective, it’s a good idea to look at blue-chip stocks to buy with a low beta.I must mention here that rate cuts are ine ...

Johnson & Johnson isn't the ultra-safe stock it used to be.Many healthcare investors look at Johnson & Johnson (JNJ 0.04%) and see a good, safe dividend stock. But I see an investment that's full of uncertainty and risk.The company continually runs into legal problems, and I can't help but wonder if one day it will follow in the path of 3M, which was also once seen as a top investment option for risk-averse investors who just wanted to collect a safe dividend; it, too, has run into many legal problems, and ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside t ...

AstraZeneca has begun the worldwide withdrawal of its COVID vaccine - ending an era in which it saved millions of lives while being dogged by controversy.The jab, developed at Oxford University, was once hailed as "the vaccine for the world" because it could be stored in fridges rather than the ultra-cold freezer temperatures originally required for alternative mRNA shots, making it more suitable for developing countries. But AstraZeneca (AZ) said demand for the jab had tailed off as more up-to-date vaccine ...

In this photo illustration a covid-19 vaccine is seen with the AstraZeneca logo in the background. (Photo Illustration by Nikos Pekiaridis/NurPhoto via Getty Images)Pharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined. The so-called Vaxzevria vaccine was developed with the University of Oxford and was one of the first shots against Covid-19 to hit the market during the coronavirus pandemic, with millions of people around the world recei ...

The pharmaceutical giant AstraZeneca said on Tuesday it is withdrawing its COVID-19 vaccine worldwide citing low demand and a "surplus of available updated vaccines" since the pandemic. The vaccine — called Vaxzevria – was one of a number of shots released onto the market by pharmaceutical companies aimed at preventing people from catching COVID-19. The company said it would proceed to withdraw Vaxzevria's marketing authorizations within Europe. The vaccine was never approved in the U.S. by the FDA. POLAND ...

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by it ...

Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (NASDAQ:AZN) completed the additional equity investm ...

ToplineThe Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk’s diabetes drug Ozempic by making it harder to produce generic drugs.The “bogus” patent listings keep brand name drug prices “artificially high,” regulators said.NurPhoto via Getty Images Key FactsThe FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca, Gl ...

A dad who suffered a brain injury just days after receiving a British-developed COVID vaccine has told Sky News he would never have had the jab if he had known of the risk of rare but serious side effects.Jamie Scott, who has two young boys and is now unable to work, is suing AstraZeneca for what he says is damage caused by the jab in April 2021. He alleges the pharmaceutical giant exaggerated the vaccine's effectiveness and downplayed its risks.AstraZeneca denies the claims made against them.In his first T ...